Evidence map›Paper›PMID 42780093›Full record

ArticleFrontiers in immunology2026

Beyond natural amino acids: extending immunogenicity risk assessment to modified peptides through chemical feature encoding. A case study on citrullination.

Maria Cairoli, Morten Nielsen, Catherine Betts, Olga Obrezanova, Leonardo De Maria

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maria CairoliDiscovery Computation and AI, Hit Discovery, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Morten NielsenDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.
Catherine BettsImmune Safety, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Olga ObrezanovaBiologics Engineering, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Leonardo De MariaDiscovery Computation and AI, Hit Discovery, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Peptide therapeutics are increasingly explored to treat challenging diseases, but immunogenicity risks limit their clinical success. Methods: Here, we present a machine learning approach combining chemical fingerprints with sequence information to predict MHC class II binding for peptides including both natural (NAA) and non-natural (NNAA) amino acids. We evaluate peptide-level fingerprints against residue-level fingerprints (direct-encoding and similarity-based fingerprints) that preserve positional information while encoding chemical diversity, for a total of 31 different representations. Results: Peptide-level fingerprints showed poor performance due to loss of positional information, while residue-level fingerprints matched the performance of sequence-based encodings (BLOSUM62 and one-hot) for NAA-based peptides while accurately identifying binding cores and motifs. Considering citrullinated peptides as a case study, we observed similar linear correlation performance across encoding strategies, with residue-level fingerprints showing marginal improvements in quantitative prediction accuracy. Citrulline was rarely found at canonical anchor positions, suggesting that the advantage of explicit chemical encoding may be more pronounced for modifications occurring at positions critical for binding. Discussion: The proposed framework allows for inclusion of diverse modifications, including synthetic amino acids, and is compatible with existing pan-allele architectures. While the full advantage of explicit chemical encoding remains to be demonstrated, this framework is designed to capture these effects as experimental data becomes available, supporting immunogenicity risk assessment for emerging peptide therapeutics.

Indexed as

Amino AcidsCitrullinePeptidesAmino Acid SequenceHistocompatibility Antigens Class IIHumansImmunoinformaticsMachine LearningPrediction AlgorithmsProtein BindingRisk AssessmentAmino AcidsCitrullineHistocompatibility Antigens Class IIPeptideschemical fingerprintsimmunogenicity risk assessmentmachine learningMHC class IInon-natural amino acidspost-translational modifications

Identifiers

PMID42780093
PMCPMC13597324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.